PDF Version for Printing
The articles referenced in this Highlights section will be available online in HTML and PDF formats to all interested users at no charge until the next issue of Cancer Research is published. Click on the article title to view the complete article.
View the Table of Contents for the February 1 issue of Cancer Research.
Page 758
Page 810
Page 932
Page 940
Hypoxic tumor cells are likely to be resistant to conventional chemotherapy, in large part because many anticancer drugs are unable to penetrate into poorly oxygenated tumor tissue. Trédan and colleagues describe the selective localization of the bioreductive prodrug AQ4N in hypoxic tumor regions and show that it complements the limited distribution of the related anticancer drug mitoxantrone. Whereas mitoxantrone is taken up by proximal cells and penetrates slowly, AQ4N rapidly penetrates tumor tissue and accumulates in hypoxic regions. These results describe a promising strategy to overcome chemoresistance due to the limited distribution of conventional anticancer agents.
Broët et al. Page 1055 Identifying high-risk patients most likely to benefit from adjuvant treatment remains an important challenge in early non–small-cell lung cancer (NSCLC). Broët and colleagues identified copy number alterations linked to survival from a series of 85 stage IB NSCLC patient samples. The authors then selected genes within these regions exhibiting copy number–driven expression to construct a novel integrated signature (IS) and found that the IS predicted clinical outcome in this series as well as in two additional independent stage I NSCLC cohorts. These results suggest that recurrent copy number alterations, when combined with gene expression information, can be successfully used to create robust predictors of clinical outcome in early-stage NSCLC.
Page 1055